

Anti-leishmanial activities of selenium nanoparticles and selenium dioxide on *Leishmania infantum*

Saied Soflaei · Abdolhossein Dalimi · Amir Abdoli ·
Mahdi Kamali · Vahid Nasiri · Mojtaba Shakibaie ·
Mahdi Tat

Received: 23 March 2012 / Accepted: 3 July 2012 / Published online: 20 July 2012
© Springer-Verlag London Limited 2012

Abstract *Leishmania infantum* is one of the important causes of visceral leishmaniasis in many countries. There are different complications for treatment of leishmaniasis such as toxicity and drug resistant. So far, there isn't any information about the effects of selenium nanoparticles and selenium dioxide (chemical form of selenium) on *Leishmania* parasites; hence, the aim of the present study is to investigate in vitro effects of six dilutions of these drugs on *L. infantum*. Anti-leishmanial activities were studied by adding different dilutions of 2.5, 5, 10, 25, 50, and 100 µg/ml of the drugs into promastigote cultures. Promastigote cytotoxicity was tested using the colorimetric MTT assay. Anti-amastigote activity was assessed in peritoneal macrophages of BALB/c mice. Also, cytotoxic effect of these drugs was evaluated on uninfected macrophages. The results showed that both of drugs have dose-dependent anti-leishmanial

activities. Selenium NPs have more growth-inhibitory effect on promastigotes than SeO₂; while the IC₅₀ (50 % inhibitory concentration) was determined to be 25 and 50 µg/ml, respectively. The mean numbers of amastigotes per macrophage in selenium NPs-treated groups were less than SeO₂-treated and control groups. The IC₅₀ of selenium NPs was 10 µg/ml and SeO₂ was 25 µg/ml for amastigotes. Also, the IC₅₀ of selenium NPs and SeO₂ for uninfected macrophages were calculated to be 100 and 50 µg/ml, respectively. In addition, selenium NPs has less cytotoxic effect than SeO₂ on uninfected macrophages. These findings suggest that selenium NPs have more anti-leishmanial properties and less cytotoxic effects than SeO₂ against *L. infantum*.

Keywords Leishmaniasis · *Leishmania infantum* · Selenium nanoparticles · Selenium dioxide · Anti-leishmanial activities

S. Soflaei · A. Dalimi (✉) · A. Abdoli · V. Nasiri
Department of Parasitology, Faculty of Medical Sciences,
Tarbiat Modares University,
Tehran 14115-331, Iran
e-mail: dalimi_a@modares.ac.ir

S. Soflaei
e-mail: S.Soflaee@hotmail.com

A. Abdoli
e-mail: a.abdoli@modares.ac.ir

M. Kamali · M. Tat
Nano-Biotechnology Research Center, Baqiyatallah
University of Medical Sciences,
Tehran, Iran

M. Kamali
e-mail: mehkamali@yahoo.co.uk

M. Shakibaie
Department of Pharmacognosy & Biotechnology,
Faculty of Pharmacy, Kerman University of Medical Sciences,
Kerman, Iran

Abbreviations

Selenium NPs Selenium nanoparticles
SeO₂ Selenium dioxide

Introduction

Visceral leishmaniasis (VL) known as kala azar is a life-threatening parasitic infection that may cause death in less developed countries. *Leishmania infantum* is one of the significant causes of visceral leishmaniasis in many countries. VL is endemic in 62 countries, with a total of 200 million people at risk and estimated 500,000 new cases each year worldwide (Guerin et al. 2002; Chappuis et al. 2007; Murray et al. 2005).

The first-line treatments for VL in many areas are pentavalent antimonials—sodium stibogluconate and meglumine antimoniate. Amphotericin B is also as the first-line treatment

for VL in some areas of the Bihar State of India. Miltefosine, which was initially developed as an anticancer drug, is the first effective oral drug for VL (Chappuis et al. 2007; Guerin et al. 2002).

There are various complications for treatment of leishmaniasis. Antimonials have several adverse side effects such as cardiac arrhythmia and acute pancreatitis (Chappuis et al. 2007; Guerin et al. 2002). Drug resistance in leishmaniasis is another significant complication. There are several cases of *Leishmania* being resistant to antimonials; resistance to miltefosine and paromomycin were reported in different countries (Maltezou 2010; Croft et al. 2006; Ait-Oudhia et al. 2011). Therefore, searching for new drugs to overcome these complications is needed.

Nanomedicine is defining the use of nanotechnology in medicine, which has been of great interest in recent years. The use of nanoparticles for therapeutics is one of the purposes of nanomedicine (Kim et al. 2010; Irache et al. 2011). In some experimental studies, nanoparticles such as nanogold and nanosilver have been used for treatment and or improvement of drug delivery in leishmaniasis (Mohebbi et al. 2009; Allahverdiyev et al. 2011; Torabi et al. 2011; Zampa et al. 2009; Durand et al. 1997a; Durand et al. 1997b; Fusai et al. 1994; Torres-Santos et al. 1999).

Selenium (Se) is a trace element with a wide range of effects in human health, including cancer prevention, antiviral activities, and antioxidant and anti-inflammatory effects (Rayman 2012). In recent years, selenium has been fabricated in nano-size with different methods including green method in bacteria (Shakibaie et al. 2010). Different in vitro and in vivo studies have been conducted on the effects of selenium NPs and other forms of selenium (Shakibaie et al. 2010; Tran and Webster 2011; Chen et al. 2003; Huang et al. 2003; Wang et al. 2005; Zhang et al. 2005; Wang et al. 2007; Zhang et al. 2004; Kuppasamy et al. 2005). The main purpose for fabricating nano-selenium is increased efficacy and decreased cytotoxicity of selenium. As previously described, nano-selenium have less cytotoxic effect but have equal efficacy in comparison with other forms of selenium (Shakibaie et al. 2010; Wang et al. 2007; Zhang et al. 2005).

To our knowledge, there aren't any reports about the effects of selenium NPs and SeO₂ (chemical form of selenium) on *Leishmania* parasites; therefore, the aim of the present study is to evaluate the effects of different dilutions/times of these drugs on *L. infantum*. The second aim of the study is to compare the cytotoxic effect of selenium NPs and SeO₂ on uninfected macrophages.

Material and methods

Selenium NPs were provided from the Department of Pharmaceutical Biotechnology and Pharmaceutical Sciences

Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences which were synthesized by green methods from SeO₂ (Shakibaie et al. 2010). SeO₂ (solubility 384 g/l at 14 °C) was prepared from Merck (Darmstadt, Germany).

Parasite culture

Promastigotes of *L. infantum* (WHO reference strain: MHOM/TN/80/IPT1) were prepared from the Pasteur Institute of Iran. For mass production, the promastigotes were cultured at 24 °C in RPMI1640 media (Gibco) supplemented with 10 % fetal calf serum (FCS) and antibiotics (100 IU/ml of penicillin and 100 µg/ml of streptomycin).

Anti-promastigote activity

Anti-promastigote assays were carried out using direct counting assay based on growth inhibition (Yousefi et al. 2009). The effects of selenium NPs and SeO₂ were evaluated in 24-well microtitre plates. The promastigotes were grown at an initial concentration equivalent to that of early log phase (2×10^6 promastigotes/ml) and then allowed to multiply for 72 h only in the RPMI medium with 10 % FCS as control group, and in the presence of different concentrations of selenium NPs and SeO₂ (2.5, 5, 10, 25, 50, and 100 µg/ml) as test groups without renewing the medium or drug. The promastigotes were counted at 24, 48, and 72 h in a hemocytometer with a light microscope. Each test was performed in triplicate and repeated in separate experiments.

Cell cytotoxicity by MTT assay

The 3-(4, 5-methylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) test is a method that measures the ability of cells in transforming the yellow tetrazolium crystals (MTT) to insoluble blue formazan dye in normal cells; dead cells are incapable of this action (Paris et al. 2004). This test was carried out using a procedure as described earlier by Verma and Dey (2004) and Paris et al. (2004), with some modification. Briefly, 100 µl of promastigotes (containing 2×10^6 cells/ml) were added to RPMI medium as control group or in the presence of six dilutions of selenium NPs and SeO₂ (2.5, 5, 10, 25, 50, and 100 µg/ml) at 24±1 °C with 5 % CO₂ for 72 h, then 20 µl of MTT solution was added into each of wells and incubated again for 4-h. After incubation, the plates were centrifuged at 6,000×g for 10 min and supernatants were aspirated gently and discarded. Finally, 100 µl DMSO was added to each of wells

mean numbers of amastigotes/macrophage was shown in Fig. 3. The IC₅₀ of selenium NPs was 10 µg/ml and SeO₂ was 25 µg/ml for amastigotes. Selenium NPs and SeO₂ have a dose-dependent effect on amastigotes. The mean numbers of amastigotes/macrophage in selenium NPs-treated groups were more than SeO₂-treated groups; these numbers were 2, 1.8, and 1.6 for SeO₂-treated groups and were 0.4, 0.2, and 0 for selenium NPs-treated groups.

Cytotoxic effect of selenium NPs and SeO₂ on macrophages

The results show that selenium NPs and SeO₂ have a dose-dependent cytotoxic effect on macrophages; while by increasing drugs concentrations, the viability was decreased (Fig. 4). Remarkably, selenium NPs have less cytotoxic effect than SeO₂ on macrophages, while the IC₅₀ of selenium NPs was 100 µg/ml and SeO₂ was 50 µg/ml. Also, the viability of selenium NPs-treated macrophages were more than SeO₂ at all dilutions/times after treatment; for example, after 72 h exposure to 100 µg/ml of both drugs, the percentages of viable macrophages were 70, 61, and 58 in selenium NPs-treated group and were 61, 56, and 51 in SeO₂-treated group.

Discussion

Our results revealed that both of drugs have dose-dependent anti-leishmanial activities. In comparison of these two drugs, selenium NPs have a more anti-leishmanial activities and less cytotoxic effects (on uninfected peritoneal macrophages) than SeO₂, while the IC₅₀ of selenium NPs for promastigote, amastigote, and macrophage was determined 25, 10 and 100 µg/ml, respectively. The IC₅₀ of SeO₂ was calculated to be 50, 10, and 50 for promastigote, amastigote, and macrophage respectively. We observed selenium NPs have less cytotoxic effect on uninfected macrophages but have more anti-amastigote and anti-promastigote activities than SeO₂.

There are some evidences that other nanoparticles such as nanosilver and nanogold have anti-leishmanial activities on *Leishmania major* and *Leishmania tropica* (Mohebbali et al. 2009; Allahverdiyev et al. 2011; Torabi et al. 2011). Also Zampa et al. (2009) observed that the nanostructure form of dermaseptin 01 (antimicrobial peptides) has in vitro anti-leishmanial activities on *Leishmania chagasi*. In addition, the use of nanoparticles for improving drug delivery was evaluated in the mouse model of visceral leishmaniasis by some workers. They showed that pentamidine bounded with nanoparticles are more potent than the free drugs for treatment of *L. infantum*-infected mice (Durand et al. 1997a, b; Fusai et al. 1994).

Previous studies revealed that selenium at nano-size can serve as antioxidant (Huang et al. 2003; Wang et al. 2007) with lower toxic effects than selenium (Wang et al. 2007; Zhang et al. 2005; Shakibaie et al. 2010). In this regard, Shakibaie et al. (2010) observed green synthesis of nano-selenium have lower toxicity than other forms of selenium in human fibrosarcoma cells. Wang et al. (2007) showed that selenium at nano-size have lower toxicity than selenomethionine but possesses equal efficacy in activities of glutathione peroxidase and thioredoxin reductase compared with selenomethionine. Also, Zhang et al. (2005) compared toxicity of nano-selenium and selenite in mice. They showed, over a short term and high dose treatment in mice, that selenite could cause more oxidative stress and liver injury than nano-selenium.

According to GuanYi et al. (2010), nano-selenium could induce apoptosis in HeLa cell line (GuanYi et al. 2010). Moreover, SeO₂ could induce apoptosis and inhibiting the telomerase activity in lung cancer cells (Chen et al. 2003). Also melatonin selenium nanoparticles could inhibit oxidative stress induced by lipopolysaccharide in mice (Wang et al. 2005). Tran and Webster (2011) also observed in vitro proliferation of *Staphylococcus aureus* inhibition by selenium nanoparticles. Other studies revealed that SeO₂ could inhibit in vitro proliferation of breast and lung cancer cells (Kuppusamy et al. 2005; Chen et al. 2003).

In conclusion, the results of our study revealed that selenium NPs and SeO₂ have dose-dependent anti-leishmanial activities. Also, selenium NPs have more anti-leishmanial activities with less cytotoxic effects than SeO₂.

References

- Ait-Oudhia K, Gazanion E, Vergnes B, Oury B, Sereno D (2011) *Leishmania* antimony resistance: what we know what we can learn from the field. *Parasitol Res* 109(5):1225–1232
- Allahverdiyev AM, Abamor ES, Bagirova M, Ustundag CB, Kaya C, Kaya F, Rafailovich M (2011) Antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light. *Int J Nanomedicine* 6:2705–2714
- Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? *Nat Rev Microbiol* 5(11):873–882
- Chen WX, Cao XZ, Zhu RZ (2003) Effect of selenium dioxide on proliferation, apoptosis, and telomerase activity of human lung cancer cell line in vitro (in Chinese with English abstract). *Chinese J Cancer* 22(9):927–931
- Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. *Clin Microbiol Rev* 19(1):111–126
- Durand R, Paul M, Rivollet D, Houin R, Astier A, Deniau M (1997a) Activity of pentamidine-loaded methacrylate nanoparticles against *Leishmania infantum* in a mouse model. *Int J Parasitol* 27(11):1361–1367

- Durand R, Paul M, Rivollet D, Fessi H, Houin R, Astier A, Deniau M (1997b) Activity of pentamidine-loaded poly (D,L-lactide) nanoparticles against *Leishmania infantum* in a murine model. *Parasite* 4(4):331–336
- Fusai T, Deniau M, Durand R, Bories C, Paul M, Rivollet D, Astier A, Houin R (1994) Action of pentamidine-bound nanoparticles against *Leishmania* on an in vivo model. *Parasite* 1(4):319–324
- Guan Yi H, Ying Z, Qiang Z, Bin Z, LongPing (2010) Vacuolization and apoptosis induced by nano-selenium in HeLa cell line. *Sci China Chem* 53(11):2272–2278
- Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. *Lancet Infect Dis* 2(8):494–501
- Huang B, Zhang J, Hou J, Chen C (2003) Free radical scavenging efficiency of Nano-Se in vitro. *Free Radic Biol Med* 35(7):805–813
- Irache JM, Esparza I, Gamazo C, Agüeros M, Espuelas S (2011) Nanomedicine: novel approaches in human and veterinary therapeutics. *Vet Parasitol* 180(1–2):47–71
- Kim BY, Rutka JT, Chan WC (2010) Nanomedicine. *N Engl J Med* 363(25):2434–2443
- Kuppusamy UR, Wan YP, Chai JW, Kanthimathi MS, Kanthimathi MS, Kuppusamy UR (2005) A comparison between selenium dioxide and selenium methionine induced cytotoxicity in estrogen receptor negative and positive breast cancer cell lines. *J Food Technol* 3:269–273
- Maltezou HC (2010) Drug resistance in visceral leishmaniasis. *J Biomed Biotechnol* 1–8. doi:10.1155/2010/617521
- Mohebbali M, Rezayat MM, Gilani K, Sarkar S, Akhouni B, Esmaili J, Satvat T, Elikae S, Charehdar S, Hooshyar H (2009) Nano-silver in the treatment of localized cutaneous leishmaniasis caused by *Leishmania major* (MRHO/IR/75/ER): an in vitro and in vivo study. *DARU* 17(4):285–289
- Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. *Lancet* 366:1561–1577
- Paris C, Loiseau PM, Bories C, Bréard J (2004) Miltefosine induces apoptosis-like death in *Leishmania donovani* promastigotes. *Antimicrob Agents Chemother* 48(3):852–859
- Rayman MP (2012) Selenium and human health. *Lancet* 379(9822):1256–1268
- Shakibaie M, Khorramizadeh MR, Faramarzi MA, Sabzevari O, Shahverdi AR (2010) Biosynthesis and recovery of selenium nanoparticles and the effects on matrix metalloproteinase-2 expression. *Biotechnol Appl Biochem* 56(1):7–15
- Torabi N, Mohebbali M, Shahverdi AR, Rezayat SM, Edrissian GH, Esmaili J, Charehdar S (2011) Nanogold for the treatment of zoonotic cutaneous leishmaniasis caused by *Leishmania major* (MRHO/IR/75/ER): an animal trial with methanol extract of *Eucalyptus camaldulensis*. *JPHS* 1:13–16
- Torres-Santos EC, Rodrigues JM, Moreira DL, Kaplan MA, Rossi-Bergmann B (1999) Improvement of in vitro and in vivo anti-leishmanial activities of 2', 6'-dihydroxy-4'-methoxychalcone by entrapment in poly (D, L-lactide) nanoparticles. *Antimicrob Agents Chemother* 43(7):1776–1778
- Tran PA, Webster TJ (2011) Selenium nanoparticles inhibit *Staphylococcus aureus* growth. *Int J Nanomedicine* 6:1553–1558
- Verma NK, Dey CS (2004) Possible mechanism of miltefosine-mediated death of *Leishmania donovani*. *Antimicrob Agents Chemother* 48(8):3010–3015
- Wang H, Wei W, Zhang SY, Shen YX, Yue L, Wang NP, Xu SY (2005) Melatonin-selenium nanoparticles inhibit oxidative stress and protect against hepatic injury induced by *Bacillus Calmette-Guérin*/lipopolysaccharide in mice. *J Pineal Res* 39(2):156–163
- Wang H, Zhang J, Yu H (2007) Elemental selenium at nano size possesses lower toxicity without compromising the fundamental effect on selenoenzymes: comparison with selenomethionine in mice. *Free Radic Biol Med* 42(10):1524–1533
- Yousefi R, Ghaffarifar F, Dalimi Asl A (2009) The effect of *Alkanna tinctoria* and *Peganum harmala* extracts on *Leishmania major* (MRHO/IR/75/ER) in vitro. *Iranian J Parasitol* 4(1):40–47
- Zampa MF, Araújo IM, Costa V, Nery Costa CH, Santos JR Jr, Zucolotto V, Eiras C, Leite JR (2009) Leishmanicidal activity and immobilization of dermaseptin 01 antimicrobial peptides in ultrathin films for nanomedicine applications. *Nanomedicine* 5(3):352–358
- Zhang J, Wang H, Bao Y, Zhang L (2004) Nano red elemental selenium has no size effect in the induction of seleno-enzymes in both cultured cells and mice. *Life Sci* 75(2):237–244
- Zhang J, Wang H, Yan X, Zhang L (2005) Comparison of short-term toxicity between Nano-Se and selenite in mice. *Life Sci* 76(10):1099–1109